Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors

NCT05055908 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

12000

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Pemetrexed plus Pembrolizumab
DRUG: Pembrolizumab
DRUG: Pemetrexed

Sponsor

Hunan Province Tumor Hospital